Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2018 On February 6, 2018

BOULDER, Colo., Jan. 30, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the second quarter of fiscal 2018 and hold a conference call to discuss those results on Tuesday, February 6, 2018.  Ron Squarer, Chief Executive Officer, will lead the call.

Webcast, including Replay and Conference Call Slides:
https://edge.media-server.com/m6/p/gwxnqcbs

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Nine registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

CONTACT:      
Array BioPharma
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications            
(303) 381-6600
ir@arraybiopharma.com

View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-second-quarter-of-fiscal-2018-on-february-6-2018-300589831.html

SOURCE Array BioPharma Inc.